Randomized Double-Blind Comparison of Single High-Dose Ondansetron and Multiple Standard-Dose Ondansetron in Chemotherapy-Naive Pediatric Oncology Patients: Original Article

• Published in: Cancer investigation 1999-01, Vol.17 (5), p.309-313
• Main Authors: Sandoval, Claudio, Corbi, Dominic, Strobino, Barbara, Ozkaynak, M. Fevzi, Tugal, Oya, Jayabose, Somasundaram
• Format: Article
• Language: English
• ISSN: 0735-7907; 1532-4192
• DOI: 10.3109/07357909909032871

This prospective, double-blind, randomized study compares the antiemetic efficacy of an equivalent dose of ondansetron administered as a single high dose or as multiple standard doses in pediatric oncology patients. Thirty-one chemotherapy-naive patients were randomized at diagnosis to receive either single high-dose ondansetron (0.6 mg/kg, maximum dose 32 mg) or multiple standard-dose ondansetron (0.15 mg/kg, maximum dose 8 mg, every 4 hr for four doses). Antiemetic efficacy was assessed by an emesis scale described as follows: 1, no nausea or emesis; 2, nauseous but able to eat; 3, nauseous and unable to eat; and 4, emesis. Sixteen patients received high-dose and 15 received standard-dose ondansetron. Patients receiving moderately or severely emetogenic chemotherapy were evenly distributed between the two treatment groups. Eighty-one percent of patients receiving high-dose and 80% receiving standard dose ondansetron rated I or 2 on the emesis scale (p = 0.93). No patient experienced any clinical or laboratory toxicity. Our study suggests that single high-dose ondansetron is as efficacious as the multiple standard-dose regimen and is well tolerated. Its use will facilitate the administration of ondansetron in pediatric patients receiving chemotherapy.